Search clinical trials for: tiotropium + placebo

Total 53909 results

Irmandade Santa Casa de Misericórdia de Porto Alegre
Novartis

Completed

Indacaterol Versus Tiotropium on Dynamic Hyperinflation in COPD

Chronic Obstructive Pulmonary Disease

Brazil
Gelb, Arthur F., M.D.
Pfizer; Boehringer Ingelheim

Completed

Tiotropium Induced Bronchodilation in Lung CT Scored Emphysema

Emphysema | COPD

United States
Assistance Publique - Hôpitaux de Paris

Unknown

Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis (RUBI)

Uveitis | Biotherapy

France
National Institute of Allergy and Infectious Diseases...

Withdrawn

Safety and Efficacy of Oseltamivir in Children Younger Than One Year of Age

Influenza
Chiesi Farmaceutici S.p.A.

Completed

Efficacy of Fixed Combination of Beclometasone + Formoterol + Glycopyrrolate in Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

Italy, Germany, Hungary
Xiromed LLC
Laboratorios Liconsa

Completed

Open Label Study to Assess the Effect of Patient Use and Robustness of Tiotropium 18ug Inhalation Powder, Hard Capsule,Zephir Inhaler Device

COPD

United States, India
Boehringer Ingelheim

Completed

Bioavailability of Tiotropium + Olodaterol Fixed-dose Combination (5 μg/ 5 μg) in Chinese COPD Patients

Pulmonary Disease, Chronic Obstructive

China
GlaxoSmithKline

Completed

The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium

Pulmonary Disease, Chronic Obstructive

Argentina, Germany, Ukraine, United States, Estonia, South Africa, Sweden, Norway, Russian Federation, Korea, Republic of
Boehringer Ingelheim

Completed

Exacerbation Risk in Asthma

Asthma

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Active, not recruiting

A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)

Chronic Obstructive Pulmonary Disease

China
Boehringer Ingelheim

Completed

Vahelva Respimat Regulatory Post-marketing Surveillance in Korean Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Korea, Republic of
Boehringer Ingelheim

Completed

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS

COPD

United States
Boehringer Ingelheim

Completed

Impact of Tiotropium Add-on Therapy in Patients With Asthma

Asthma

United States
Boehringer Ingelheim

Completed

A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Japan
Novartis Pharmaceuticals

Completed

Long Term Safety and Tolerability of NVA237 Versus Tiotropium in Japanese Patients (GLOW4)

Chronic Obstructive Pulmonary Disease

Japan
GlaxoSmithKline

Completed

A Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

Influenza, Human

United States
University of Nottingham
Quadram Institute Bioscience

Recruiting

Effect of Methylcellulose or Psyllium on Fermentation of inUlin Assessed USing MRI (RUFUS)

Colon, Irritable

United Kingdom
Novo Nordisk A/S

Completed

Effect of Two Different Fasting Blood Glucose Targets on Glucose Control in Patients With Type 2 Diabetes Using Insulin Detemir Once Daily (TITRATE™)

Diabetes Mellitus, Type 2 | Diabetes

United States, Puerto Rico
Boehringer Ingelheim

Completed

Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients After Switching to Tiotropium Plus Olodaterol Fixed Dose Combination in Greece

Pulmonary Disease, Chronic Obstructive

Greece
Novartis Pharmaceuticals

Completed

A Randomized, Multicenter, Open-label, Parallel-group, 12-week Study to Assess the Efficacy and Safety of Switching From Tiotropium to QVA149 (Indacaterol Maleate/Glycopyrronium Bromide) in Symptomatic Mild to Moderate COPD Patients

COPD

Korea, Republic of
Novartis Pharmaceuticals

Withdrawn

Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

China
University Hospital, Basel, Switzerland

Completed

Effects of Interleukin-1 Receptor Antagonism on Hyperandrogenemia in Women With Polycystic Ovary Syndrome (FertIL)

Polycystic Ovary Syndrome

Switzerland
Boehringer Ingelheim

Completed

Characterization of Lung Function Profile of Inhaled Tiotropium + Olodaterol Fixed Dose Combination Compared to Fluticasone Propionate + Salmeterol Fixed Dose Combination in COPD Patients

Pulmonary Disease, Chronic Obstructive

Belgium, Czech Republic, Denmark, Germany, Hungary, Netherlands, Spain, Sweden
Boehringer Ingelheim

Terminated

Assessment of Health-related Quality of Life After Switching COPD Patients From a Dry Powder Inhaler to a Soft Mist Inhaler Remaining on the Same Inhalative Drug (NIS PIRATE)

Pulmonary Disease, Chronic Obstructive

Switzerland
Boehringer Ingelheim

Completed

Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study

Pulmonary Disease, Chronic Obstructive

United States
Chiesi Farmaceutici S.p.A.

Completed

Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Hungary
Boehringer Ingelheim

Completed

Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan

Pulmonary Disease, Chronic Obstructive

China
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Argentina, Australia, United States, Germany, Chile, Korea, Republic of, Mexico, Canada, South Africa, Romania
University of Saskatchewan

Completed

Duration of Long Acting Muscarinic Antagonist (LAMA) Bronchoprotection Against Methacholine Challenge

Asthma

Canada
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Germany
University of Milan
Fondazione Salvatore Maugeri

Completed

Closing Volume Interpretation and Bronchodilators Effect

Healthy | COPD

Italy
Boehringer Ingelheim

Completed

A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.

Pulmonary Disease, Chronic Obstructive

United Kingdom, Turkey, United States, Greece, Portugal, Finland, Italy, Sweden
Boehringer Ingelheim

Completed

Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Comparative Effectiveness of COPD Treatments

Pulmonary Disease, Chronic Obstructive

Canada
Shanghai Zhongshan Hospital

Unknown

Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

China
Otsuka Pharmaceutical, Inc., Philippines
Otsuka Pharmaceutical Co., Ltd.

Terminated

Tiotropium + Procaterol vs Tiotropium + Placebo in COPD Patients

Pulmonary Disease, Chronic Obstructive

Philippines
Brigham and Women's Hospital

Completed

Replication of the POET-COPD Trial in Healthcare Claims Data

Chronic Obstructive Pulmonary Disease

United States
Huashan Hospital

Unknown

Efficiency of Twice Daily Formoterol Versus Once Daily Tiotropium in Patients With GOLD A/B COPD (FACT)

Chronic Obstructive Pulmonary Disease

China
GlaxoSmithKline

Completed

Safety And Efficacy Of GSK233705 Plus Salmeterol Compared With 2 Active Comparators And Placebo In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Germany, Netherlands, Finland, Russian Federation, United Kingdom
RWTH Aachen University

Withdrawn

Cardiac Effects of Spiolto®/Respimat® in Patients With Congestive Heart Failure and COPD (CREATES)

COPD

Germany
Boehringer Ingelheim

Completed

A Comparison of the Effects of Tiotropium Inhalation qd and Salmeterol Inhalation Bid on Arterial Blood Gases.

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Inhaled Corticosteroid Withdrawal in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Australia, Belgium, Brazil, Bulgaria, China, Denmark, France, Germany, Greece, Hungary, Italy, Netherlands, New Zealand, Philippines, Poland, Russian Federation, South Africa, Spain, Taiwan, Tunisia, Turkey, Ukraine, United Kingdom
Pearl Therapeutics, Inc.

Completed

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of PT001, PT003, and PT005 Following Chronic Dosing (7 Days) in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Australia, United States, New Zealand
University of Dundee

Completed

Ultra-long Acting Bronchodilator Therapy in Smoking Asthmatics (MAN05)

Asthma

United Kingdom
GlaxoSmithKline

Completed

24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States, Russian Federation, Ukraine, Germany, Peru, Poland, France, Romania, Italy, Mexico
Pearl Therapeutics, Inc.

Completed

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Australia, New Zealand
James J. Peters Veterans Affairs Medical Center
Kessler Institute for Rehabilitation

Unknown

Effects of Anticholinergic or Long-Acting Beta 2 Agonist on FeNO and Pulmonary Function in SCI

Spinal Cord Injury

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium Inhalation Capsules and Atrovent MDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Taiwan
Boehringer Ingelheim

Completed

A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Spain, Canada, Germany

3

Subscribe